Veno–Venous Extracorporeal Life Support (VV ECLS) Devices Market : Global Forecast over 2026

Veno–venous Extracorporeal Life Support (VV ECLS) Devices are observed with up-surging demand with increasing incidences and prevalence for cardiopulmonary disease and respiratory failure disorder. The veno – venous extracorporeal life support (VV ECLS) devices has shown promising results for pediatric and neonatal patients suffering with acute respiratory distress syndrome (ARDS) and single-ventricle physiology. It has recorded with improved outcome compared to venoarterial ECLS for cardiopulmonary disease treatment. According NCBI article (2016), Veno–venous Extracorporeal Life Support (VV ECLS) offers survival rate of about 48% which comparably high than venoarterial ECLS with 32% survival rate. Both arterial and venous thrombi possess a substantial risk in patients with single-ventricle disorder due to the vulnerability of the coronary, pulmonary and cerebral circulations. Veno–venous Extracorporeal Life Support (VV ECLS) Devices.

The experience with cannula placement continues to evolve in Veno–venous Extracorporeal Life Support (VV ECLS). Thus, Veno–venous Extracorporeal Life Support (VV ECLS) devices market is classified based on type of cannula in single ventricle patients as, veno-venous double lumen (VVDL), Single lumen and others. Based on location of application, the market for Veno–venous extracorporeal life support (VV ECLS) devices is classified into jugular vein, right atrium, femoral vein and others. The Veno–venous extracorporeal life support (VV ECLS) devices has reported effective results in jugular vein and right atrium. The Veno–venous Extracorporeal Life Support (VV ECLS) Devices has reported use in both single-ventricle patients and biventricular patients. However, due to reported effective results of the Veno–venous extracorporeal life support (VV ECLS) devicesin single-ventricle patients has increased the scope for the devices in the market.

The major factors driving the global Veno–venous extracorporeal life support (VV ECLS) devices market are rising incidences of cardiopulmonary disease and respiratory failure, increasing awareness about cardiopulmonary disease and respiratory failure, rising need for cardiopulmonary monitoring and treatment system like Veno–venous extracorporeal life support (VV ECLS) devices, etc. According to report published by WHO in 2015, 17.5 million people died due to cardiopulmonary disease which represents more than 30% of the global death. Factors contributing to increasing prevalence of cardiopulmonary diseases are growing aging population, changing lifestyle, increasing disposable income, smoking, etc.

Veno–venous extracorporeal life support (VV ECLS) devices market has anticipated to grow at significant growth rate in next few years owing to increase in the patient pool suffering from cardiopulmonary diseases. The conditions like dizziness, bluish extremities, shortness of breath, chest pain, chest pain, hypertension, hypertension, wheezing, etc., that may radiate to the jaw or arms, anxiety sudden sweating and nausea or vomiting. And over the time, symptoms may further worsen, which can be a life threatening if not treated instantly. The use of Veno–venous extracorporeal life support (VV ECLS) devices assists the patients for maintaining the body to normal level through appropriate intervention. With significant scope, Veno–venous extracorporeal life support (VV ECLS) devices market has anticipated to imbibe a high potential with a significant growth rate.

Geographically, the market has been categorized in five main regions: North America, Europe, Latin America, Asia – Pacific and the Middle East and Africa. Increasing prevalence of cardiopulmonary diseases, growing aging population and active intervention by government like “Million Hearts” initiative by US government to spread awareness about risk associated with cardiopulmonary diseases are the factors contributing to the growth of Veno–venous extracorporeal life support (VV ECLS) devices market in North America, and followed by Europe.

In addition, the market in North America is expected to grow rapidly due to high demand for new and innovative products. According to a recent report by the Japan Aging Research Center, the Asia–Pacific is on the verge of suffering from aging of population. Japan, China, and South Korea are the countries experiencing highest problem of aging population followed to rising risk for cardiopulmonary diseases. The growing prevalence of cardiovascular and cardiopulmonary diseases in Asia will be responsible for increase in cardiopulmonary diseases burden across the region. The region also constitutes some of the developed markets such as Australia and New Zealand. These nations possess well established infrastructure along with high awareness and huge demand for Veno–venous extracorporeal life support (VV ECLS) devices and is expected to propel the market.

Request to view Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-2475

The Key players operating in the global Veno–venous extracorporeal life support (VV ECLS) devices market are AQUETHolding B. V. & Co. KG, Microport Scientific Corporation, Medos Medizintechnik AG, Sorin Group, Medtronic, Plc., Terumo Cardiovascular Systems Corporation, and Nipro Medical Corporation, etc.